Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 210

1.

Integrative Biomarker Analyses Indicate Etiological Variations in Hepatocellular Carcinoma.

Zhu AX, Chen D, He W, Kanai M, Voi M, Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY.

J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30147-7. doi: 10.1016/j.jhep.2016.04.015. [Epub ahead of print]

PMID:
27130844
2.

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.

Chong DQ, Zhu AX.

Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8775. [Epub ahead of print] Review.

3.

Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.

Saha SK, Zhu AX, Fuchs CS, Brooks GA.

Oncologist. 2016 Mar 21. pii: theoncologist.2015-0446. [Epub ahead of print]

PMID:
27000463
4.

Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON.

Oncologist. 2016 Apr;21(4):514-20. doi: 10.1634/theoncologist.2015-0267. Epub 2016 Mar 14.

PMID:
26975868
5.

Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma.

Deshpande V, Konstantinidis IT, Castillo CF, Hezel AF, Haigis KM, Ting DT, Bardeesy N, Goyal L, Zhu AX, Warshaw AL, Lillemoe KD, Ferrone CR.

J Gastrointest Surg. 2016 May;20(5):953-9. doi: 10.1007/s11605-016-3108-0. Epub 2016 Mar 8.

PMID:
26956004
6.

CT-Guided Percutaneous Microwave Ablation of Tumors in the Hepatic Dome: Assessment of Efficacy and Safety.

Asvadi NH, Anvari A, Uppot RN, Thabet A, Zhu AX, Arellano RS.

J Vasc Interv Radiol. 2016 Apr;27(4):496-502. doi: 10.1016/j.jvir.2016.01.010. Epub 2016 Feb 28.

PMID:
26922977
7.

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Hato T, Zhu AX, Duda DG.

Immunotherapy. 2016 Mar;8(3):299-313. doi: 10.2217/imt.15.126. Epub 2016 Feb 11.

PMID:
26865127
8.

Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX.

J Clin Oncol. 2016 Feb 10;34(5):460-8. doi: 10.1200/JCO.2015.64.2710. Epub 2015 Dec 14.

PMID:
26668346
9.

Impact of intravenous contrast enhancement phase on target definition for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC): Observations from patients enrolled on a prospective phase 2 trial.

Niska JR, Keane FK, Wolfgang JA, Hahn PF, Wo JY, Zhu AX, Hong TS.

Pract Radiat Oncol. 2016 Jan-Feb;6(1):e9-e16. doi: 10.1016/j.prro.2015.08.005. Epub 2015 Aug 28.

PMID:
26598907
10.

Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N.

Nature. 2015 Dec 3;528(7580):152. doi: 10.1038/nature16136. Epub 2015 Nov 18. No abstract available.

PMID:
26580013
11.

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.

Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-Del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR.

Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.

PMID:
26373575
12.

Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

PLoS One. 2015 Sep 14;10(9):e0136725. doi: 10.1371/journal.pone.0136725. eCollection 2015.

13.

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.

Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N, Zheng H, Zhu AX.

Oncologist. 2015 Sep;20(9):1019-27. doi: 10.1634/theoncologist.2015-0210. Epub 2015 Aug 5.

PMID:
26245674
14.

Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

J Comput Assist Tomogr. 2015 Sep-Oct;39(5):687-96. doi: 10.1097/RCT.0000000000000288.

PMID:
26222909
15.

Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.

Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H.

Acad Radiol. 2015 Nov;22(11):1344-60. doi: 10.1016/j.acra.2015.05.012. Epub 2015 Jul 23.

PMID:
26211553
16.

Changes in land use, climate and the environment during a period of rapid economic development in Jiangsu Province, China.

Huang C, Zhang M, Zou J, Zhu AX, Chen X, Mi Y, Wang Y, Yang H, Li Y.

Sci Total Environ. 2015 Dec 1;536:173-81. doi: 10.1016/j.scitotenv.2015.07.014. Epub 2015 Jul 21.

PMID:
26204053
17.

An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.

Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX, Bardeesy N, Jain RK, Duda DG.

Nat Protoc. 2015 Aug;10(8):1264-74. doi: 10.1038/nprot.2015.080. Epub 2015 Jul 23.

PMID:
26203823
18.

Chemotherapy and antiangiogenics in biliary tract cancer.

Goyal L, Chong DQ, Duda DG, Zhu AX.

Lancet Oncol. 2015 Aug;16(8):882-3. doi: 10.1016/S1470-2045(15)00093-5. Epub 2015 Jul 12. No abstract available.

19.

Consensus conference on hilar cholangiocarcinoma.

Forsmark CE, Diniz AL, Zhu AX.

HPB (Oxford). 2015 Aug;17(8):666-8. doi: 10.1111/hpb.12451. No abstract available.

PMID:
26172133
20.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk